A new study, published in eLife, uses advanced tissue analysis technology to show how the incorporation of new proteins changes in bone and cartilage with age.
Inhye Park has been awarded a Novo Nordisk Postdoctoral Research Fellowship to research the biology of resident vascular macrophages in atherosclerosis.
A two-day student symposium returned to the Kennedy Institute bringing together students and peers from across the department to discuss their latest research.
Building work at the Kennedy Institute of Rheumatology has finished, providing a new third floor that houses additional meeting and collaboration space for data science and offices for the management of clinical trials.
Jethro Johnson, Deputy Director of the Oxford Centre for Microbiome Studies explains how the centre is building a research community to understand the microbiome and harness its power to promote health and prevent disease.
As part of the University of Oxford\u2019s mission to provide its researchers with the newest state-of-the-art optical imaging equipment and as part of a strategic partnership with the Kennedy Institute of Rheumatology (KIR), the Institute of Developmental and Regenerative Medicine (IDRM), and Carl Zeiss AG (ZEISS), ZEISS has installed a ZEISS Lattice Lightsheet 7 microscope at the KIR.
New research shows that disrupting primary cilia in juvenile, adolescent and early adulthood in cartilage stops it maturing correctly, making it more prone to thinning and the potential for osteoarthritis (OA) in later life.
Postdoctoral Researcher Ghada Alsaleh has been awarded a research grant by Versus Arthritis which she will use to develop a new therapy for osteoarthritis.
A new study published in Circulation Research by researchers at the Kennedy Institute shows that CD200, an inhibitory immune checkpoint, reduces the development of atherosclerosis.
Researchers at the Kennedy Institute join a collaboration to find new \u2018drug-free\u2019 ways of treating illnesses where current treatments have become ineffective due to antibiotic resistance.
Professor Michael Dustin and an international team of collaborators have been awarded a \u20ac10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.
Oxford researchers have used advanced microscopy techniques to measure previously unseen forces generated by cells during an immune response; a breakthrough for mechanobiology and future advances in health and disease.
![\"View](\"https://www.kennedy.ox.ac.uk/news/labelling-proteins-through-the-diet-gives-new-insights-into-how-collagen-rich-tissues-change-as-we-age/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n